MC2 Therapeutics

MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora(R) Cream for treatment of Plaque Psoriasis

MC2 Therapeutics: MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA(R) Cream, in the US

MC2 Therapeutics: MC2 Therapeutics Announces U.S. Food and Drug Administration Approval of Wynzora(R) Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) for Adults with Plaque Psoriasis

MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head trial Comparing Wynzora(TM) Cream to Daivobet(R) Gel in Patients with Psoriasis